Rocio Gonzalez-Conejero

List of Publications by Year
in descending order

112 papers	2,957 citations	159585 30 h-index	206112 48 g-index
112 all docs	112 docs citations	112 times ranked	3453 citing authors

#	Article	IF	Citations
1	Polymorphisms of Platelet Membrane Glycoprotein Ibîœ€ Associated With Arterial Thrombotic Disease. Blood, 1998, 92, 2771-2776.	1.4	168
2	Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFÎ±. Arthritis Research and Therapy, 2015, 17, 49.	3.5	158
3	Biological Assessment of Aspirin Efficacy on Healthy Individuals. Stroke, 2005, 36, 276-280.	2.0	136
4	Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood, 2007, 109, 4258-4263.	1.4	104
5	The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. British Journal of Haematology, 1997, 99, 304-307.	2.5	92
6	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. Journal of the American College of Cardiology, 2009, 54, 1041-1057.	2.8	92
7	Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients. Journal of Autoimmunity, 2017, 82, 31-40.	6.5	82
8	Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. Blood, 2001, 97, 2979-2982.	1.4	79
9	Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood, 2009, 113, 4977-4979.	1.4	73
10	MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 892-902.	2.4	66
11	A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood, 2006, 108, 177-183.	1.4	58
12	Role of Fibrinogen Levels and Factor XIII V34L Polymorphism in Thrombolytic Therapy in Stroke Patients. Stroke, 2006, 37, 2288-2293.	2.0	54
13	Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. British Journal of Haematology, 2007, 137, 99-108.	2.5	54
14	Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. Journal of Thrombosis and Haemostasis, 2004, 2, 931-939.	3.8	53
15	Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis. Human Reproduction, 2015, 30, 2292-2302.	0.9	51
16	â€˜Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patientsâ€™. Scientific Reports, 2016, 6, 31375.	3.3	44
17	Homozygous Deficiency of Heparin Cofactor II. Circulation, 2004, 110, 1303-1307.	1.6	43
18	The number of platelet glycoprotein Ia molecules is associated with the genetically linked 807 C/T and HPAâ€5 polymorphisms. Transfusion, 1999, 39, 372-378.	1.6	41

#	Article	IF	Citations
19	miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. Haematologica, 2021, 106, 1636-1646.	3.5	39
20	Detection of Factor V Leiden from a Drop of Blood by PCR-SSCP. Thrombosis and Haemostasis, 1996, 76, 735-737.	3.4	39
21	Polymorphisms of P-selectin glycoprotein ligand-1 are associated with neutrophil-platelet adhesion and with ischaemic cerebrovascular disease. British Journal of Haematology, 2001, 115, 969-976.	2.5	38
22	The association of the Â1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica, 2007, 92, 513-518.	3.5	38
23	Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thrombosis and Haemostasis, 2009, 101, 483-486.	3.4	37
24	Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. Journal of Molecular and Cellular Cardiology, 2004, 37, 699-704.	1.9	36
25	miR-133a Regulates Vitamin K 2,3-Epoxide Reductase Complex Subunit 1 (VKORC1), a Key Protein in the Vitamin K Cycle. Molecular Medicine, 2012, 18, 1466-1472.	4.4	36
26	Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 781-788.	3.4	36
27	Prothrombin A19911G and G20210A polymorphisms' role in thrombosis. British Journal of Haematology, 2002, 118, 610-614.	2.5	35
28	The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. Journal of Thrombosis and Haemostasis, 2007, 5, 1701-1706.	3.8	34
29	Regulation of Coagulation Factor XI Expression by MicroRNAs in the Human Liver. PLoS ONE, 2014, 9, e111713.	2.5	34
30	Migraine and prothrombotic genetic risk factors. Cephalalgia, 1998, 18, 257-260.	3.9	32
31	Prothrombotic Genetic Risk Factors in Patients With Coexisting Migraine and Ischemic Cerebrovascular Disease. Headache, 1999, 39, 486-489.	3.9	30
32	The TFPI 536C â†'T Mutation Is not Associated with Increased Risk for Venous or Arterial Thrombosis. Thrombosis and Haemostasis, 2000, 83, 787-788.	3.4	30
33	Creating a genotype-based dosing algorithm for acenocoumarol steady dose. Thrombosis and Haemostasis, 2013, 109, 146-153.	3.4	30
34	Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. Haematologica, 2018, 103, 908-918.	3.5	30
35	Quality assessment of platelet concentrates supplemented with second-messenger effectors. Transfusion, 1999, 39, 135-143.	1.6	28
36	The role of microRNAâ€27a/b and microRNAâ€494 in estrogenâ€mediated downregulation of tissue factor pathway inhibitor Î±. Journal of Thrombosis and Haemostasis, 2016, 14, 1226-1237.	3.8	28

#	Article	IF	Citations
37	Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction. Thrombosis and Haemostasis, 2005, 94, 1294-1299.	3.4	27
38	A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. Journal of the American College of Cardiology, 2005, 45, 25-29.	2.8	27
39	Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. American Journal of Cardiology, 2003, 91, 1242-1245.	1.6	25
40	Genetic Polymorphisms of Platelet Adhesive Molecules: Association with Breast Cancer Risk and Clinical Presentation. Breast Cancer Research and Treatment, 2003, 80, 145-154.	2.5	24
41	Platelet GP IIIa Polymorphism HPA-1 (PlA) Protects Against Subarachnoid Hemorrhage. Stroke, 2004, 35, 2282-2286.	2.0	24
42	microRNAs in the haemostatic system: More than witnesses of thromboembolic diseases?. Thrombosis Research, 2018, 166, 1-9.	1.7	23
43	Effect of <scp>CYP</scp>4F2,<scp>VKORC</scp>1, and <scp>CYP</scp>2C9 in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23
44	New alleles of the platelet glycoprotein IbÎ± gene. British Journal of Haematology, 1998, 103, 997-1003.	2.5	22
45	Polymorphisms of Platelet Adhesive Receptors: Do They Play a Role in Primary Intracerebral Hemorrhage?. Cerebrovascular Diseases, 2003, 15, 51-55.	1.7	22
46	Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. Journal of Thrombosis and Haemostasis, 2010, 8, 1012-1017.	3.8	22
47	Detection of conformational transformation of antithrombin in blood with crossed immunoelectrophoresis: new application for a classical method. Translational Research, 2003, 142, 298-305.	2.3	21
48	Regulation of TFPIÎ± expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens. Scientific Reports, 2017, 7, 43500.	3.3	20
49	Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists. Thrombosis Research, 2020, 185, 119-124.	1.7	20
50	MiRNA-Based Regulation of Hemostatic Factors through Hepatic Nuclear Factor-4 Alpha. PLoS ONE, 2016, 11, e0154751.	2.5	19
51	Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. American Heart Journal, 2004, 148, 602-605.	2.7	18
52	miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. Leukemia, 2020, 34, 2648-2659.	7.2	18
53	Platelet Cryopreservation Using a Reduced Dimethyl Sulfoxide Concentration and Second-Messenger Effectors as Cryopreserving Solution. Cryobiology, 1999, 39, 1-12.	0.7	17
54	MicroRNAs as New Regulators of Neutrophil Extracellular Trap Formation. International Journal of Molecular Sciences, 2021, 22, 2116.	4.1	17

#	Article	IF	Citations
55	Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. Haematologica, 2005, 90, 421-3.	3.5	17
56	Association of autoantibodies against platelet glycoproteins Ib/IX and IIb/IIIa, and plateletâ€reactive antiâ€HIV antibodies in thrombocytopenic narcotic addicts. British Journal of Haematology, 1996, 93, 464-471.	2.5	16
57	Genotypeâ€“phenotype relationship for six common polymorphisms in genes affecting platelet function from 286 healthy subjects and 160 patients with mucocutaneous bleeding of unknown cause. British Journal of Haematology, 2009, 146, 95-103.	2.5	16
58	Plasma levels of Von Willebrand factor are increased in patients with hypertrophic cardiomyopathy. Thrombosis Research, 2010, 126, e46-e50.	1.7	16
59	miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis. PLoS ONE, 2018, 13, e0198932.	2.5	16
60	Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements. PLoS ONE, 2013, 8, e64469.	2.5	16
61	Role of Genetic Polymorphisms in NFKB-Mediated Inflammatory Pathways in Response to Primary Chemoradiation Therapy for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 595-602.	0.8	15
62	Neutrophil extracellular traps and von Willebrand factor are allies that negatively influence COVIDâ€19 outcomes. Clinical and Translational Medicine, 2021, 11, e268.	4.0	15
63	Implications of Pharmacogenetics for Oral Anticoagulants Metabolism. Current Drug Metabolism, 2009, 10, 632-642.	1.2	15
64	Factor VII â€“323 decanucleotide D/I polymorphism in atrial fibrillation: Implications for the prothrombotic state and stroke risk. Annals of Medicine, 2008, 40, 553-559.	3.8	14
65	MicroRNAs as potential regulators of platelet function and bleeding diatheses. Platelets, 2019, 30, 803-808.	2.3	14
66	Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer. Bone Marrow Transplantation, 1999, 23, 621-624.	2.4	13
67	Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: a case control study. BMC Cancer, 2013, 13, 228.	2.6	13
68	Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas. Annals of Hematology, 2014, 93, 243-247.	1.8	13
69	Neutrophil extracellular trap components increase the expression of coagulation factors. Biomedical Reports, 2019, 10, 195-201.	2.0	13
70	Role of Factor Xiii Val 34 Leu Polymorphism in Patients with Migraine. Cephalalgia, 2001, 21, 837-841.	3.9	12
71	The â^'1C>T mutation in the annexin A5gene does not affect plasma levels of annexin A5. Blood, 2003, 101, 4223-4224.	1.4	12
72	CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. Annals of Medicine, 2010, 42, 439-446.	3.8	12

#	Article	IF	Citations
73	Influence of the F12-4 C>T polymorphism on hemostatic tests. Blood Coagulation and Fibrinolysis, 2010, 21, 632-639.	1.0	11
74	CALU polymorphism A29809G affects calumenin availability involving vascular calcification. Journal of Molecular and Cellular Cardiology, 2015, 82, 218-227.	1.9	11
75	Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. Journal of Clinical Medicine, 2020, 9, 3645.	2.4	11
76	miR-146a in Cardiovascular Diseases and Sepsis: An Additional Burden in the Inflammatory Balance?. Thrombosis and Haemostasis, 2021, 121, 1138-1150.	3.4	11
77	A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood, 2002, 100, 2081-6.	1.4	11
78	Latent and polymeric antithrombin: clearance and potential thrombotic risk. Experimental Biology and Medicine, 2007, 232, 219-26.	2.4	11
79	Complejo plaquetario GP Ib/IX/V: papel fisiolÃ³gico. Journal of Physiology and Biochemistry, 2000, 56, 355-365.	3.0	10
80	Molecular, ultrastructural and functional characterization of a Spanish family with Hermansky-Pudlak syndrome: role of insC974 in platelet function and clinical relevance. British Journal of Haematology, 2003, 123, 132-138.	2.5	10
81	Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. Annals of Medicine, 2010, 42, 562-575.	3.8	10
82	Control of post-translational modifications in antithrombin during murine post-natal development by miR-200a. Journal of Biomedical Science, 2013, 20, 29.	7.0	10
83	Genotype-guided therapy improves initial acenocoumarol dosing. Thrombosis and Haemostasis, 2016, 115, 117-125.	3.4	10
84	Factor XIII Val34Leu polymorphism in primary intracerebral haemorrhage. The Hematology Journal, 2000, 1, 269-273.	1.4	10
85	Evaluation of Leukocyte–Depleted Platelet Concentrates Obtained by In–Line Filtration. Vox Sanguinis, 2000, 78, 235-241.	1.5	10
86	Role of GSTT1 and M1 null genotypes as risk factors for Bâ€cell lymphoma: Influence of geographical factors and occupational exposure. Molecular Carcinogenesis, 2012, 51, 508-513.	2.7	9
87	Protein Z-dependent protease inhibitor W303X mutation in venous thrombosis. British Journal of Haematology, 2005, 129, 561-562.	2.5	8
88	Effect ofVKORC1, CYP2C9andCYP4F2genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics, 2014, 15, 987-996.	1.3	8
89	Platelet activation and neutrophil extracellular trap (NET) formation in immune thrombocytopenia: is there an association?. Platelets, 2020, 31, 906-912.	2.3	8
90	Prognostic value of annexin A5 ?1 C/T polymorphism in a long term follow-up after premature myocardial infarction. Journal of Thrombosis and Haemostasis, 2007, 5, 862-863.	3.8	6

#	Article	IF	Citations
91	Uniparental disomy causes deficiencies of vitamin Kâ€dependent proteins. Journal of Thrombosis and Haemostasis, 2016, 14, 2410-2418.	3.8	6
92	Comparative Study of Three Methods to Detect Free Plasma Antiplatelet Antibodies. Acta Haematologica, 1996, 96, 135-139.	1.4	5
93	Coexistence of three genetic risk factors in a Spanish thrombophilic family: Factor V Leiden, prothrombin 20210 and a new type I antithrombin deficiency. Thrombosis and Haemostasis, 2007, 97, 153-155.	3.4	5
94	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. European Journal of Clinical Investigation, 2018, 48, e12929.	3.4	5
95	Identification of Circulating microRNA Signatures As Potential Noninvasive Biomarkers for Prediction to Response to Extracorporeal Photoapheresis in Patients with Graft Versus Host Disease. Blood, 2019, 134, 4466-4466.	1.4	5
96	Mutation analysis of HPS1, the gene mutated in Hermansky-Pudlak syndrome, in patients with isolated platelet dense-granule deficiency. Haematologica, 2004, 89, 325-9.	3.5	5
97	Genetic variants of the extra-large stimulatory Gs protein alpha-subunit and risk of thrombotic and haemorrhagic disorders. British Journal of Haematology, 2004, 125, 621-628.	2.5	4
98	Effect of factor VII -323 Del/Ins polymorphism on the daily variability of factor VIIc and INR in steady anticoagulated patients with acenocoumarol. Journal of Thrombosis and Haemostasis, 2004, 2, 2264-2265.	3.8	4
99	Î³-glutamyl carboxylase R325Q polymorphism on the response of acenocoumarol. Thrombosis Research, 2008, 122, 429-431.	1.7	4
100	The PI3KÎ´ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential. International Journal of Molecular Sciences, 2021, 22, 3304.	4.1	4
101	Polymorphisms of Platelet Membrane Glycoprotein Ibîœ€ Associated With Arterial Thrombotic Disease. Blood, 1998, 92, 2771-2776.	1.4	4
102	Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thrombosis and Haemostasis, 2009, 101, 483-6.	3.4	4
103	Prognostic and Predictive Effects of Tumor and Plasma miR-200c-3p in Locally Advanced and Metastatic Breast Cancer. Cancers, 2022, 14, 2390.	3.7	4
104	Factor-V (Arg⁵⁰⁶â†'Gln) Mutation in Ischemic Cerebrovascular Disease. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1997, 27, 105-111.	0.3	3
105	Platelet aggregation through prothrombinase activation induced by non-aggregant doses of platelet agonists. Blood Coagulation and Fibrinolysis, 2002, 13, 95-103.	1.0	3
106	A novel mutation in the antithrombin gene (insT 7429â€“30) causes superior mesenteric vein thrombosis. Thrombosis Research, 2007, 119, 793-796.	1.7	3
107	Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders. Annals of Hematology, 2010, 89, 1147-1154.	1.8	3
108	A Radioreceptor Assay for Mass Measurement of Inositol (1,4,5)-Trisphosphate Using Saponin-Permeabilized Outdated Human Platelets. Analytical Biochemistry, 1998, 256, 117-121.	2.4	2

#	Article	IF	Citations
109	Synergism between factor XII â€“4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction. Thrombosis and Haemostasis, 2010, 104, 650-652.	3.4	2
110	Coexistence of three genetic risk factors in a Spanish thrombophilic family: Factor V Leiden, prothrombin 20210 and a new type I antithrombin deficiency. Thrombosis and Haemostasis, 2007, 97, 153-5.	3.4	2
111	Fluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated. Future Cardiology, 2006, 2, 197-203.	1.2	0
112	rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling. Blood, 2018, 132, 3072-3072.	1.4	0